Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Cancer immunotherapy continues to evolve as a promising approach to treatment, focusing on enhancing the immune system's ability to identify and attack cancer cells. A critical aspect of immunotherapy is the effective presentation of tumor antigens to the immune system. However, many tumor antigens are hidden within the tumor cells and are not easily accessible for traditional immune activation. One of the key processes for enhancing the immune response is cross-presentation, which allows dendritic cells (DCs) to present intracellular antigens to CD8+ cytotoxic T cells, crucial for targeting cancer cells.
Autophagosome Pulsed Dendritic Cell (DC) Development Service leverages the natural autophagy process to enhance cross-presentation. Autophagy is a cellular mechanism that involves the degradation and recycling of intracellular components, including tumor-associated proteins. By utilizing autophagosomes—vesicles containing degraded tumor proteins—we can significantly improve the presentation of these tumor antigens by dendritic cells. This method ensures that dendritic cells are able to present both surface and intracellular tumor antigens, thereby activating a broader and more robust immune response.
At Creative Biolabs, our Autophagosome Pulsed Dendritic Cell (DC) Development Service is designed to optimize the cross-presentation of tumor antigens, enabling the activation of CD8+ T cells and enhancing the overall immune response against cancer. This innovative approach offers a more comprehensive and targeted immunotherapy strategy.
Our Autophagosome Pulsed Dendritic Cell (DC) Development Service is specifically designed to harness the power of autophagy to improve tumor antigen presentation. By loading dendritic cells with autophagosomes containing tumor-specific antigens, we enable dendritic cells to cross-present these antigens to T cells, enhancing the immune system's ability to target and destroy cancer cells.
Key steps involved in our service include:
We isolate autophagosomes from tumor cells, which contain intracellular tumor antigens. These autophagosomes are rich in tumor-associated proteins and provide a broad range of antigens that are essential for the immune system to recognize and attack cancer cells.
Dendritic cells are isolated from the patient's peripheral blood or from other immune cell sources. These cells are then cultured and matured under specific conditions to ensure they can effectively present antigens to T cells.
The autophagosomes containing tumor antigens are introduced into the matured dendritic cells. The dendritic cells internalize these autophagosomes, process the tumor antigens, and present them to CD8+ cytotoxic T cells for immune activation.
After the pulsing process, the dendritic cells are tested for their ability to cross-present the tumor antigens and activate T cells. The hybrid cells are also evaluated for their viability, functionality, and efficiency in triggering immune responses.
The autophagosome-pulsed dendritic cells are tailored to the unique characteristics of the patient's tumor. This personalized approach ensures that the most relevant antigens are presented to maximize immune response and improve therapeutic outcomes.
Our service maximizes the cross-presentation of tumor antigens, particularly intracellular proteins, which are often difficult to target with conventional immunotherapies. This improves the activation of CD8+ cytotoxic T cells, crucial for eliminating cancer cells.
The service is fully customizable, allowing us to tailor the pulsed dendritic cells to present the most relevant antigens from a patient's tumor, ensuring a targeted and highly effective immune response.
Autophagosomes contain a wide range of tumor antigens, including those that are intracellular, providing a more comprehensive pool of antigens for dendritic cells to present. This ensures a broader immune response capable of recognizing a wider array of tumor markers.
With years of experience in dendritic cell biology and cancer immunotherapy, Creative Biolabs offers a high-quality, reliable service backed by advanced technologies and expert knowledge in the field.
The autophagosome-pulsed dendritic cells can be used in various immunotherapeutic applications, including personalized cancer vaccines, adoptive T-cell therapies, and immune adjuvant therapies.
Q1. What is autophagy and why is it important in cancer immunotherapy?
A1: Autophagy is a cellular process that breaks down and recycles internal components, including proteins and organelles. In cancer immunotherapy, autophagy allows dendritic cells to capture and present intracellular tumor antigens, which are essential for activating a targeted immune response.
Q2. How does cross-presentation enhance the immune response?
A2: Cross-presentation allows dendritic cells to present both extracellular and intracellular tumor antigens to CD8+ cytotoxic T cells. This broadens the immune system's ability to recognize and destroy cancer cells, particularly those that have internal antigens that are otherwise difficult to target.
Q3. How are autophagosomes collected and used in this service?
A3: Autophagosomes are isolated from tumor cells and contain a variety of tumor antigens. These autophagosomes are introduced into dendritic cells, which process the antigens and present them to T cells, triggering an immune response.
Q4. Is this service suitable for all types of cancer?
A4: Yes, our Autophagosome Pulsed Dendritic Cell (DC) Development Service can be applied to a wide range of cancers, as it can be customized to the specific tumor profile of each patient. This ensures that the most relevant antigens are presented for optimal immune activation.
At Creative Biolabs, we are committed to providing innovative and personalized solutions in cancer immunotherapy. Our Autophagosome Pulsed Dendritic Cell (DC) Development Service is designed to enhance tumor antigen presentation and improve immune response. If you have any questions or would like to learn more about how this service can be applied to your cancer research or treatment development, please don't hesitate to contact us.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
